ArticleFrontiers in oncology2026

Real-world evidence of lower-dose intensity of immune checkpoint inhibitors in MSI-H/dMMR gastrointestinal cancers from a resource-constrained setting.

Mohamad Mourad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.